Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Xenobiotica; the fate of foreign compounds in biological systems

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1080/00498250802069088 PMID 18570162
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs

  2007cited by this paper
• Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.

  2006cited by this paper
• A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics

  2006cited by this paper
• Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat.

  2005cited by this paper
• Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort.

  2005cited by this paper
• Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

  2005cited by this paper
• Comparison of the Use of Liver Models for Predicting Drug Clearance Using in Vitro Kinetic Data from Hepatic Microsomes and Isolated Hepatocytes

  2004cited by this paper
• Prediction of Human Drug Clearance from in Vitro and Preclinical Data Using Physiologically Based and Empirical Approaches

  2004cited by this paper
• Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.

  2003cited by this paper
• The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets

  2003cited by this paper
• Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

  2003cited by this paper
• Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047

  2002cited by this paper
• Cross-Resistance among Nonnucleoside Reverse Transcriptase Inhibitors Limits Recycling Efavirenz after Nevirapine Failure

  2002cited by this paper
• Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs.

  2001cited by this paper
• Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors

  2001cited by this paper
• Predicting the impact of physiological and biochemical processes on oral drug bioavailability.

  2001cited by this paper
• Adverse effects of antiretroviral therapy.

  2000cited by this paper
• A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery.

  2000cited by this paper
• Clinical uses of non‐nucleoside reverse transcriptase inhibitors

  2000cited by this paper
• A compartmental absorption and transit model for estimating oral drug absorption.

  1999cited by this paper
• Physiological Parameter Values for Physiologically Based Pharmacokinetic Models

  1997cited by this paper
• Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2 receptor antagonists in the isolated perfused rat liver.

  1995cited by this paper
• An improved method for the determination of distribution coefficients

  1990cited by this paper
• Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin

  1980cited by this paper

• Antioxidant, Diabetic and Inflammatory Activities of Alpinia calcarata Roscoe Extract

  2023cites this paper
• Characterisation of AMB-FUBINACA metabolism and CB1-mediated activity of its acid metabolite

  2022cites this paper
• Qualification and application of liquid chromatography-quadrupole time-of-flight mass spectrometric method for the determination of carisbamate in rat plasma and prediction of its human pharmacokinetics using physiologically based pharmacokinetic modeling

  2020cites this paper
• Quantitative Analysis of Tozadenant Using Liquid Chromatography-Mass Spectrometric Method in Rat Plasma and Its Human Pharmacokinetics Prediction Using Physiologically Based Pharmacokinetic Modeling

  2019cites this paper
• Building in-house PBPK modelling tools for oral drug administration from literature information

  2019cites this paper
• Absolute Oral Bioavailability of Creatine Monohydrate in Rats: Debunking a Myth

  2018cites this paper
• Performance evaluation of the GastroPlusTM software tool for prediction of the toxicokinetic parameters of chemicals

  2018cites this paper
• Prediction of a Therapeutic Dose for Buagafuran, a Potent Anxiolytic Agent by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Starting from Pharmacokinetics in Rats and Human

  2017cites this paper
• Quantitative Systems Pharmacology: A Framework for Context

  2016cites this paper
• Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels

  2016cites this paper
• Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model

  2015cites this paper
• Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human.

  2015cites this paper
• Discovery of a Selective TRPM8 Antagonist with Clinical Efficacy in Cold-Related Pain.

  2015cites this paper
• The Discovery of Potent Nonstructural Protein 5A (NS5A) Inhibitors with a Unique Resistance Profile—Part 2

  2014cites this paper
• The Discovery of Potent Nonstructural Protein 5A (NS5A) Inhibitors with a Unique Resistance Profile—Part 1

  2014cites this paper
• Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility

  2014cites this paper
• Lersivirine – a new drug for HIV infection therapy

  2013cites this paper
• Non-benzimidazole containing inhibitors of respiratory syncytial virus.

  2013cites this paper
• Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data

  2012cites this paper
• Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism‐based adverse events

  2012cites this paper
• Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches

  2012cites this paper
• Developmental toxicity study of lersivirine in mice.

  2012cites this paper
• Medicinal chemistry approaches to avoid aldehyde oxidase metabolism.

  2012cites this paper
• Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies

  2012cites this paper
• Application of PBPK modelling in drug discovery and development at Pfizer

  2012cites this paper
• Comparison of the Non‐Nucleoside Reverse Transcriptase Inhibitor Lersivirine with its Pyrazole and Imidazole Isomers

  2011cites this paper
• PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.

  2011cites this paper
• Have physiologically-based pharmacokinetic models delivered?

  2011cites this paper
• Physiologically-based pharmacokinetics in drug development and regulatory science.

  2011cites this paper
• Preclinical and Clinical Pharmacokinetics of PF-02413873, a Nonsteroidal Progesterone Receptor Antagonist

  2011cites this paper
• An update on computational oral absorption simulation

  2011cites this paper
• From definition to implementation: a cross-industry perspective of past, current and future MIST strategies

  2011cites this paper
• Measurement of Binding of Basic Drugs to Acidic Phospholipids Using Surface Plasmon Resonance and Incorporation of the Data into Mechanistic Tissue Composition Equations to Predict Steady-State Volume of Distribution

  2011cites this paper
• Lersivirine to Healthy Volunteers

  2010influential citation
• Excretion and Metabolism of Lersivirine (5-{[3,5-Diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a Next-Generation Non-Nucleoside Reverse Transcriptase Inhibitor, after Administration of [14C]Lersivirine to Healthy Volunteers

  2010cites this paper
• Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease

  2010influential citation
• Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations

  2009influential citation
• Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor α agonist in preclinical species and human

  2009influential citation
• The Simcyp population-based ADME simulator.

  2009cites this paper
• Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling

  2009cites this paper
• A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates.

  2009cites this paper
• Population-Based Mechanistic Prediction of Oral Drug Absorption

  2009cites this paper
• Pyrazole NNRTIs 3: optimisation of physicochemical properties.

  2009cites this paper
• Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.

  2009cites this paper
• The Simcyp® Population-based ADME Simulator

  2009cites this paper
• A holistic strategy for characterizing the safety of metabolites through drug discovery and development.

  2009cites this paper
• Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients

  2009cites this paper
• Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.

  2009cites this paper